Abstract：
UNASSIGNED: Administrationof allergen mixtures of many components comprises the most common approach forAmerican allergists regarding the management of polyallergic patients. Europeanallergists, however, are more reluctant to this type of treatment due to thepotential drawbacks of mixing extracts.
UNASSIGNED: To assess theefficacy and safety of subcutaneous immunotherapy (SCIT) with polymerizedallergen mixtures without dilutional effect in polyallergic patients.Thisobservational, prospective, multicenter study included patients (between 5-60 years) with respiratory allergic diseases that had been prescribed with SCITwith mixtures of two pollen or mite extracts. Changesin Symptoms and Medication Score (SMS) and in rhinitis quality of life questionnaire (RQLQ), subjective clinicalimprovement, treatment satisfaction and tolerability were assessed after the1-year treatment.
UNASSIGNED: 115 patientswere included in the assessment. Mean global SMS decreased from 3.5 (SD = 1.1) to1.6 (SD = 1.2) points, with a meanabsolute reduction of 1.6 (SD = 1.3) points in the RQLQ score (p < 0.001, Wilcoxon test). General subjective clinical improvements anda good treatment satisfaction and tolerability were observed.
UNASSIGNED: SCIT with polymerizedallergen mixtures from either pollen or mite extracts proved to be an effectiveand safe treatment option for polyallergic patients suffering from allergicrespiratory diseases.
UNASSIGNED: To assess theefficacy and safety of subcutaneous immunotherapy (SCIT) with polymerizedallergen mixtures without dilutional effect in polyallergic patients.Thisobservational, prospective, multicenter study included patients (between 5-60 years) with respiratory allergic diseases that had been prescribed with SCITwith mixtures of two pollen or mite extracts. Changesin Symptoms and Medication Score (SMS) and in rhinitis quality of life questionnaire (RQLQ), subjective clinicalimprovement, treatment satisfaction and tolerability were assessed after the1-year treatment.
UNASSIGNED: 115 patientswere included in the assessment. Mean global SMS decreased from 3.5 (SD = 1.1) to1.6 (SD = 1.2) points, with a meanabsolute reduction of 1.6 (SD = 1.3) points in the RQLQ score (p < 0.001, Wilcoxon test). General subjective clinical improvements anda good treatment satisfaction and tolerability were observed.
UNASSIGNED: SCIT with polymerizedallergen mixtures from either pollen or mite extracts proved to be an effectiveand safe treatment option for polyallergic patients suffering from allergicrespiratory diseases.
摘要：
■施用多种成分的过敏原混合物包括美国变态反应学家关于多变态反应患者管理的最常用方法。欧洲变态反应学家，然而,由于混合提取物的潜在缺点，更不愿意进行这种类型的处理。
■评估在多变态反应患者中使用聚合变应原混合物进行皮下免疫疗法（SCIT）的有效性和安全性。这个观察，prospective,多中心研究包括患有呼吸道过敏性疾病的患者（5-60岁），这些患者已与SCIT一起使用两种花粉或螨提取物的混合物。改变症状和药物治疗评分（SMS）和鼻炎生活质量问卷（RQLQ），主观临床改善，在治疗1年后评估治疗满意度和耐受性.
■115名患者纳入评估。全球平均SMS从3.5(SD=1.1)下降到1.6(SD=1.2)点，RQLQ评分平均绝对减少1.6(SD=1.3)分(p<0.001,Wilcoxon检验)。观察到总体主观临床改善以及良好的治疗满意度和耐受性。
■含有花粉或螨提取物的聚合物过敏原混合物的SCIT被证明是患有过敏性呼吸系统疾病的多过敏患者的有效和安全的治疗选择。
■评估在多变态反应患者中使用聚合变应原混合物进行皮下免疫疗法（SCIT）的有效性和安全性。这个观察，prospective,多中心研究包括患有呼吸道过敏性疾病的患者（5-60岁），这些患者已与SCIT一起使用两种花粉或螨提取物的混合物。改变症状和药物治疗评分（SMS）和鼻炎生活质量问卷（RQLQ），主观临床改善，在治疗1年后评估治疗满意度和耐受性.
■115名患者纳入评估。全球平均SMS从3.5(SD=1.1)下降到1.6(SD=1.2)点，RQLQ评分平均绝对减少1.6(SD=1.3)分(p<0.001,Wilcoxon检验)。观察到总体主观临床改善以及良好的治疗满意度和耐受性。
■含有花粉或螨提取物的聚合物过敏原混合物的SCIT被证明是患有过敏性呼吸系统疾病的多过敏患者的有效和安全的治疗选择。
